Unlocking the potential of
genomic medicine

Overview



Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary10/15/2019
PHILADELPHIA , Oct. 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and granted the
Toggle Summary08/07/2019
Plan to enter Phase 2 in Adult Onset Still's Disease and other serious rare and orphan diseases PHILADELPHIA , Aug. 7, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase
Toggle Summary08/06/2019
PHILADELPHIA , Aug. 6, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that Michael F. Cola , President and Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 1:20 p.m.

Recent Presentations

More >>
There are no items to display.

Upcoming Events

More >>
There are currently no events to display.

Recent Events

More >>
Date Event Details
Summary Toggle
Monday,May 23,2011 4:30 pm +04

Medgenics Inc at 10th Annual Israeli Life Sciences Industry Biomed 2011 Conference

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright West LLC. Minimum 15 minutes delayed.